DATAVAULT AI INC
DVLTNASDAQTrading Snapshot
- Day Range
- $0.07 – $0.11
- 52-Week Range
- $0.12 – $4.10
- Volume (shares)
- 383,273,826
- Avg Volume (shares)
- —
- Shares Outstanding
- 949.7M
- Next Earnings
- 2026-11-16
Fundamentals Snapshot
- Annual Revenue
- $39M
- Last Q Revenue
- $7M
- P/E Ratio
- —
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-0.54
- Dividend Yield
- —
- Dilution (1yr)
- +2832.3%
DATAVAULT AI INC
DVLT
StockOtter · stockotter.spaceAbout DATAVAULT AI INC
Datavault operates as a data science technology firm, specializing in secure data management within the Web 3.0 environment. Its core expertise spans blockchain integration, artificial intelligence, and innovative approaches to data monetization. The company's unique, patented platform is designed to empower users with the ability to visualize, accurately value, and securely commercialize their data holdings. This robust system is utilized across a range of industries, including but not limited to marketing, real estate, and various government applications.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to Know
Shares of Datavault AI Inc. (NASDAQ:DVLT) fell nearly 40% after the company told investors to stop relying on financial results stretching back to the third quarter of 2025.
Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RW
DataMeds Regains Compliance With NASDAQ Listing Standards
TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure tog
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("Dat
Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption
Allowed patent application covers asset valuation, tokenization, transaction verification, and blockchain-enabled marketplaces as a new federal framework opens the door to on-chain trading of tokenized stocks PHILADELPHI
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"